Comparing Peak Bio (NASDAQ:PKBO) & Zura Bio (NASDAQ:ZURA)

Peak Bio (NASDAQ:PKBO) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Peak Bio and Zura Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0	0	0	0	N/A
Zura Bio	0	0	6	1	3.14

Zura Bio has a consensus target price of $19.80, indicating a potential upside of 485.80%. Given Zura Bio’s higher probable upside, analysts plainly believe Zura Bio is more favorable than Peak Bio.

Earnings & Valuation

This table compares Peak Bio and Zura Bio’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Bio	$610,000.00	0.34	-$13.09 million	N/A	N/A
Zura Bio	N/A	N/A	-$69.24 million	N/A	N/A

Peak Bio has higher revenue and earnings than Zura Bio.

Profitability

This table compares Peak Bio and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	N/A
Zura Bio	N/A	-64.56%	-50.33%

Insider & Institutional Ownership

61.1% of Zura Bio shares are held by institutional investors. 19.9% of Peak Bio shares are held by company insiders. Comparatively, 15.8% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Peak Bio has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.